GlassScriptPhysician profile
Elizabeth Chacko
NPI 1528337391
$1,404.10
in general payments reported to CMS, 2019-2025
23 companies · $43.29 in 2025
The $43.29 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21.13 · 2021: $291 · 2022: $151 · 2023: $323 · 2024: $575 · 2025: $43.29.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $941.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $941.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $267.33 | 2022-2024 | Mounjaro, Lyumjev, Zepbound |
| Corcept Therapeutics | $164.32 | 2023-2025 | Korlym |
| Novo Nordisk INC | $118.71 | 2021-2024 | |
| Radius Health, INC. | $100.65 | 2021-2024 | Tymlos |
| Xeris Pharmaceuticals, INC. | $93.42 | 2023-2024 | Recorlev, Gvoke Hypopen |
| Dexcom, INC. | $82.05 | 2021-2025 | Dexcom G6 Transmitter |
| Tandem Diabetes Care, INC. | $76.50 | 2022-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.04 | 2019-2023 | Jardiance, Synjardy |
| Insulet Corporation | $56.66 | 2021-2024 | Omnipod |
| Sanofi-Aventis U.S. LLC | $48.51 | 2021-2022 | |
| Medtronic, INC. | $41.96 | 2021-2023 | Minimed 780g |
| Becton, Dickinson and Company | $39.20 | 2021 | |
| Alexion Pharmaceuticals, INC. | $37.68 | 2024 | Strensiq |
| Embecta Corp. | $32.46 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Bayer Healthcare Pharmaceuticals INC. | $24.83 | 2024 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $23.86 | 2024 | |
| Abbott Laboratories | $20.80 | 2022 | |
| Abbvie INC. | $20.05 | 2021 | |
| Lifescan, INC. | $19.39 | 2021 | |
| Nevro Corp. | $17.67 | 2023 | Senza |
| Horizon Therapeutics Plc | $17.48 | 2021 | |
| Cequr Corporation | $16.07 | 2024 | Cequr Simplicity |
| Astrazeneca Pharmaceuticals LP | $12.46 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Chacko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.